Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic ...
The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...
A novel approach using native mass spectrometry has significantly advanced the understanding of stabilization mechanisms of ...
Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...
A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...
Fujifilm Kyowa Kirin Biologics granted Mylan an exclusive licence to commercialise its version of adalimumab, Hulio, in Europe. Amgen, Biogen and Samsung Bioepis have all have been granted ...
Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; bit.bio cuts 25% of workforce
Story Feb. 4 - Kyowa Kirin: The Japanese pharma is letting go ... shrinking its head count by 40% and reassessing the future of Amgen-partnered T-cell engager CX-904 as a way to save cash and ...
The recent approvals and robust pipeline activity are expected to fuel the market of molecular glues in the 7MM during the forecast period 2025-2034 due to factors like improved diagnosis, treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback